查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1479851

醣质学市场 - 2024 年至 2029 年预测

Glycomics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 130 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

醣质学市场预计将从 2022 年的 1,438,251,000 美元增加到 2029 年的 2,360,017,000 美元，预测期内复合年增长率为 7.33%。

由于几个关键因素，醣质学市场正在经历显着的成长和扩张。关键驱动力之一是持续开发新的和增强的聚醣分析技术。质谱仪和聚醣微阵列等设备的进步使得对聚醣的分析变得更加灵敏和特异性，从而推动了市场成长。

此外，政府津贴的增加以及製药和生物技术公司的研究投资在推动市场扩张方面发挥关键作用。随着研究人员对聚醣在健康和疾病中的作用有了更深入的了解，对醣质学工具和技术的需求不断增加。

另一个重要的驱动因素是对个人化医疗的日益重视。聚醣为了解个体差异和疾病感受性提供了宝贵的见解，有助于开发更有针对性的治疗方法。

此外，印度医药市场预计到 2024 年将达到 650 亿美元，到 2030 年将达到 1,300 亿美元，这对改进诊断工具的需求做出了巨大贡献。

印度供应了全球50%以上的各种疫苗需求和美国40%的非专利需求，而癌症、糖尿病和自体免疫疾病等慢性病盛行率的上升是由对先进诊断方法的需求所推动的。强调了这一必要性。

醣质学在满足这一需求方面前景广阔，有可能为这些疾病开发新的诊断方法。

慢性病快速增加

癌症、糖尿病和自体免疫疾病等慢性病的增加需要增强诊断能力。醣质学代表了针对这些疾病创新新诊断方法的有前途的途径。

在全球范围内，由于久坐的生活方式、人口老化和环境污染等因素，慢性病呈现上升趋势。这些疾病，包括癌症、糖尿病和自体免疫疾病，给世界各地的医疗系统带来了巨大的负担。

非传染性疾病（NCD）也称为慢性病，通常病程较长，是由遗传、生理、环境和行为因素的复杂交互作用所引起。

据世界卫生组织称，心血管疾病是最致命的非传染性疾病，每年约导致1790 万人死亡，其次是癌症（930 万人）和慢性呼吸道疾病（410 万人死亡）和糖尿病（200 万人，其中包括200 万人）。

聚醣对于许多生物过程至关重要，其结构和功能的变化与许多慢性疾病的发病和进展密切相关。例如，在癌细胞中发现异常糖链，并导致肿瘤生长和转移。同样，在糖尿病和自体免疫疾病患者中观察到聚醣谱的偏差。

俄罗斯和乌克兰之间持续的衝突预计将对醣质学市场产生微妙的影响。战争扰乱了全球供应链，导致醣质学研究必需的原材料和设备短缺且价格飙升。设备和试剂所需的许多关键材料可能生产这些地区，导致延误并影响研究活动。

此外，衝突正在导致全球经济严重不稳定，这可能导致政府和私人组织的研究经费减少。这可能对整体市场成长构成主要障碍。

然而，在这些挑战中，衝突可能会加强全球对生物准备和创新诊断和治疗开发的重视。此外，现有供应链的中断可能导致调查所必需的关键材料和设备的生产区域化。

醣质学酶细分市场的成长预测

糖基转移酶等酶对于醣质学至关重要，因为它们合成糖链并降解碳水化合物。聚醣结构由糖基化酶形成，凝集素有助于识别糖链。了解这些酵素对于破解聚醣在生物学中的功能（从疾病病因学到细胞讯号传导）是必要的。他们的研究有助于开发特定糖链的诊断药物和治疗方法。

不断发展的生物医学行业依赖糖酶进行药物发现、诊断和治疗方法，并且认识到聚醣是重要的生物标记和治疗标靶。学术界、工业界和研究机构的共同努力正在推动新型醣质学酶的开发，这些酶专为从工业生物技术到医学的各种应用而定制，进一步推动了成长轨迹。

据缅因州政府 DECD 称，到 2022 年，缅因州的生物医学製造业将需要 30 亿美元的活动，其中 23 亿美元（77%）将来自州外。缅因州生物医学製造业的国外进口额为 1.201 亿美元。缅因州 5.1% 的进口需求是透过从州外进口来满足的，这表明用于生物医学製造的进口产品 94.9% 是在当地采购的。此外，导航、测量、医疗和控制仪器是 2022 年缅因州最主要的进口产品之一，估计价值 9,000 万美元。到 2022 年，这将占州外进口总额的 1.1%。

此外，由于科学研究、技术进步和工业应用扩大等多种因素，聚醣相关酵素的数量正在增加。随着研究揭示聚醣在生物过程和疾病机制中发挥的复杂功能，对参与聚醣合成、修饰、酶工程和降解的酶的需求不断增加。

由于潜在蛋白质的搜寻空间广泛，酶工程通常涉及寻找具有某些所需活性的酶的起点，然后进行受控进化以增加其对特定应用的「适用性」。据 OSTI 称，机器学习 (ML) 近年来已成为支援这种启发式方法的强大工具。

总体而言，由于生物医学应用的增加、研究的增长和技术的改进，酶市场预计将显着增长。市场参与企业有很多机会创造适合工业生物技术、诊断和药物开发需求的独特酵素。这为该领域的创新和资金筹措开闢了可能性，进一步刺激了市场。

鼓励研究的政府计划，例如向大学提供研究津贴贷款，刺激创新和团队合作，并帮助扩大市场。此外，支持醣质学技术在医学和商业中使用的监管法规也透过营造有利于醣质学酶商业化和接受的氛围来支持市场成长。

鞘醣脂对于神经系统中的细胞识别和通讯至关重要。近年来，异常糖基化在癌症研究中引起了越来越多的关注，主要集中在两个方面。 FDA核准的大多数肿瘤标记是糖蛋白或糖类抗原，异常糖基化是一种非侵入性肿瘤生物标记物，糖基化对于癌症的发生、进展和转移至关重要。

此外，根据欧盟委员会的说法，GlycoHIT 的目标是创建一种用于临床样本中蛋白质糖基化分析的高通量 (HTP) 技术，重点是早期、准确和快速检测癌症。对于探索性研究目的，目前的蛋白质糖基化分析方法，例如质谱 (MS) 和高效液相层析(HPLC) 是合适的。蛋白质糖基化的 HTP 分析需要新的技术平台和现有技术的进一步发展。此外，GlycoHIT 合作将突破目前技术的极限，创造未来技术，从而对从临床和生物製药样本中获得的蛋白质进行更快速、更多元化的糖基化分析。

除了策略上专注于联盟和收购以扩大产品系列和市场占有率外，市场参与企业还投资于研发，以生产具有扩展功能的创新酶。例如，Creative Proteomics 提供 O-聚醣结合分析服务、N-聚醣结合分析服务、糖蛋白质体学服务、O-聚醣分析和 N-聚醣分析等服务。

预计北美地区市场将会成长。

随着慢性病负担的增加，开发新药变得必要。聚醣与多种疾病有关，包括癌症、心臟病和感染疾病，并参与多种生物过程。例如，根据美国癌症协会的数据，美国新患者估计为男性 983,160 例，女性 934,870 例。

此外，了解聚醣概况以及它们如何与蛋白质和细胞相互作用对于确定潜在的治疗标靶和设计有效的药物是必要的。在美国，由于药物发现和药物开发过程的整合，药物筛检平台、伴同性诊断和改进的基于聚醣的疗法也在开发中。

此外，在美国，药物发现和药物开发中对聚醣靶向的关注正在增加对研发和技术的需求，提供了显着的成长前景。例如，透明质酸是一种天然存在的糖胺聚醣Glico单元，在医学上有多种用途。它应用于手术伤口，在骨关节炎的治疗中发挥重要作用。对先进治疗的需求不断增加以及政府对研发的资助增加，支持了当地产业的成长。例如，2023年4月，NIH启动了Glico计划，以鼓励糖科学领域的糖生物学研究。Glico计划创建了多种工具、资源和讯息，以帮助不熟悉聚醣的研究人员将其纳入他们的研究中。这包括识别特别困难的聚醣的方法、用于研究细菌细胞壁中的聚醣的探针、聚醣化学合成的标准、高通量聚醣研究的方法以及与糖科学相关的工具。

许多产品为学术、製药和研究机构的研究人员的实验和研究提供了便利。其他公司则专注于将研究成果转化为有用的商业应用。这些公司为各种市场生产和销售基于聚醣的产品，包括营养补充、生物製药和诊断。例如，安捷伦科技公司于 2023 年 6 月推出了 Agilent BioTek 406 FX 清洗分配器。这是一款集板清洗和多用途试剂分配功能于一体的小型设备。 BioTek 406 FX 具有扩展的液体处理功能，既适合独立桌面使用，也适合整合到自动化系统中。

此外，赛默飞世尔科技于 2022 年 9 月推出了 DynaSpinTM 抛弃式离心机系统。该系统专门为大规模细胞培养物收穫提供理想的一次性选择。此外，它透过减少完成收穫过程所需的深度过滤滤芯的数量，增强和简化了一次性生物过程中细胞培养分离的收穫。

主要参与企业

  • Merck KGaA 是醣质学市场的领先参与企业，为聚醣分析和研究提供广泛的产品和解决方案。 Merck KGaA 专注于创新和技术，为研究人员提供工具和试剂来推进他们的醣质学研究。
  • Thermo Fisher Scientific Inc. 是醣质学市场的另一家领先参与企业，以其专注于聚醣分析的全面分析仪器、耗材和软体解决方案组合而闻名。
  • Takara Bio Inc.提供高品质的试剂、套件和设备。我们专注于简化工作流程和提高实验重现性，提供创新的解决方案来支援聚醣分析并加速该领域的发现。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章醣质学市场：副产品

  • 介绍
  • 酵素
  • 装置
  • 套件
  • 其他的

第六章醣质学市场：依应用分类

  • 介绍
  • 药物发现
  • 诊断
  • 其他的

第七章醣质学市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 有竞争力的仪表板

第九章 公司简介

  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • Takara Bio Inc.
  • Shimadzu Corporation
  • Agilent Technologies, Inc.
  • New England Biolabs
  • Asparia Glycomics
  • Z Biotech, LLC.
  • QA-Bio
简介目录
Product Code: KSI061613965

The glycomics market is anticipated to grow at a compound annual growth rate (CAGR) of 7.33% over the forecast period to reach US$2,360.017 million by 2029, increasing from US$1,438.251 million in 2022.

The glycomics market is experiencing significant growth and expansion, driven by several key factors. One major driver is the continuous development of new and enhanced technologies for glycan analysis. Advancements in instruments such as mass spectrometers and glycan microarrays enable more sensitive and specific analysis of glycans, thus propelling the market growth.

Moreover, increased government funding and investments by pharmaceutical and biotech companies in glycomics research play a crucial role in driving market expansion. As researchers delve deeper into understanding the role of glycans in health and disease, the demand for glycomics tools and techniques continues to rise.

Another important driver is the growing emphasis on personalized medicine. Glycans provide valuable insights into individual variations and disease susceptibility, facilitating the development of more targeted therapies.

Additionally, the Indian pharmaceutical market, currently valued at $65 billion in 2024 and projected to reach $130 billion by 2030, is contributing significantly to the demand for improved diagnostic tools.

With India supplying over 50% of the global demand for various vaccines and 40% of the generic demand in the US, the rising prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders further emphasizes the need for advanced diagnostic methods.

Glycomics, with its potential for developing novel diagnostic approaches for these diseases, holds immense promise in meeting this demand.

Surge in chronic diseases

The increasing prevalence of chronic illnesses such as cancer, diabetes, and autoimmune conditions is driving the demand for enhanced diagnostic capabilities. Glycomics present a promising avenue for innovating new diagnostic methodologies tailored to these ailments.

Globally, chronic diseases are on the ascent, a trend attributable to factors like sedentary lifestyles, aging populations, and environmental pollutants. These conditions, which include cancer, diabetes, and autoimmune disorders, impose substantial burdens on healthcare systems worldwide.

Noncommunicable diseases (NCDs), also referred to as chronic diseases, are typically prolonged in duration and result from a complex interplay of genetic, physiological, environmental, and behavioral elements.

According to WHO, cardiovascular diseases claim the most lives among NCDs, accounting for approximately 17.9 million fatalities annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including deaths related to kidney disease caused by diabetes).

Glycans are integral to numerous biological processes, and alterations in their structure and function are closely linked to the onset and advancement of many chronic ailments. For example, abnormal glycans are identified in cancer cells, contributing to tumor proliferation and metastasis. Similarly, deviations in glycan profiles are observed in individuals with diabetes and autoimmune disorders.

The ongoing conflict between Russia and Ukraine is expected to have a nuanced effect on the Glycomics market. The war has resulted in disruptions to global supply chains, leading to scarcities and price escalations for essential raw materials and equipment utilized in glycomics research. Many critical materials required for instruments and reagents may originate from these regions, causing delays and impacting research endeavors.

Furthermore, the conflict has induced substantial economic instability worldwide, potentially resulting in reduced research funding from both governmental sources and private entities. This could pose a significant obstacle to overall market growth.

However, amidst these challenges, the conflict may intensify the global emphasis on biopreparedness and the development of innovative diagnostics and therapeutics. Additionally, the disruption of existing supply chains may prompt a shift towards regionalization of production for key materials and equipment essential to glycomics research.

The glycomics enzymes segment is estimated to grow

Enzymes such as glycosyltransferases are essential to glycomics because they synthesize glycoconjugates and degrade carbohydrates. Glycan structures are shaped by glycan-modifying enzymes, and lectins help recognize glycans. Deciphering the functions of glycans in biology, ranging from causes of disease to cell signaling, requires an understanding of these enzymes. Their research aids in the creation of diagnostics and treatments based on glycans.

The growing biomedical industry is dependent on glycomic enzymes for drug discovery, diagnosis, and treatment approaches, driven by the understanding that glycans are important biomarkers and targets for therapeutics. The development of novel glycomics enzymes is customized to a range of applications, from industrial biotechnology to healthcare, and is driven by joint efforts among academia, industry, and research organizations, which further fuel the growth trajectory.

In 2022, as per the DECD (Government of Maine), the biomedical manufacturing sector in Maine required $3.0 billion in activity; of that amount, $2.3 billion, or 77%, came from outside the state. Maine's biomedical manufacturing industry imports are worth $120.1 million from overseas. 5.1% of Maine's import demand is satisfied by imports from outside the state, suggesting that local sources account for 94.9% of all imports of goods used in biomedical manufacturing. Furthermore, instruments for navigation, measurement, medicine, and control rank as the top imports into Maine in 2022, with an estimated value of $90 million. In 2022, this represents 1.1% of total imports from outside the state.

Furthermore, glycomic enzymes are increasing due to various factors, including scientific study, technical advancements, and growing industrial applications. The need for enzymes involved in glycan synthesis, modification, enzyme engineering, and degradation is growing as research reveals the complex functions that glycans play in biological processes and disease mechanisms.

Enzyme engineering often entails finding an enzyme starting point that has some degree of the desired activity, followed by controlled evolution to increase its "fitness" for a specific application, due to the large search space of potential proteins. As per the OSTI, Machine learning (ML) has become a potent tool to support this empirical approach in recent times.

Comprehensively, the glycomics enzymes market is expected to increase significantly due to rising biomedical applications, growing research, and technological improvements. Market participants have many opportunities to create unique enzymes that are suited to the needs of industrial biotechnology, diagnostics, and medication development. This opens the door for more innovation and funding in this field, further fueling the market.

Government programs that encourage glycomics research, such as grants for research and financing for universities, are stimulating innovation and teamwork, which is propelling the market's expansion. Furthermore, regulatory regulations that support the use of glycomics technologies in healthcare and business also aid in market growth by fostering an atmosphere that is favorable for the commercialization and acceptance of glycomics enzymes.

Glycosphingolipids are crucial for cell identification and communication in the nervous system. Abnormal glycosylation has drawn increasing attention in cancer research in the past few years, primarily in two areas. The majority of FDA-approved tumour markers are glycoprotein or glycan antigens, and aberrant glycosylation is a non-invasive tumour biomarker, glycosylation is crucial to the onset, progression, and metastasis of cancer.

Furthermore, as per the European Commission, the goal of GlycoHIT has been to create high throughput (HTP) technologies for the analysis of protein glycosylation in clinical samples, with a focus on early, precise, and fast cancer detection. For the goal of discovery research, current methods for analysing protein glycosylation, such as mass spectrometry (MS) and high-performance liquid chromatography (HPLC), are appropriate. To undertake HTP analysis of protein glycosylation, new technical platforms and additional advancements in already-existing technologies are required. In addition, to create future technologies that allow for quicker and multiplexed analysis of glycosylation on proteins from clinical and biopharmaceutical samples, the GlycoHIT collaboration pushes the boundaries of current technology.

In addition to strategically concentrating on alliances and acquisitions to broaden their product portfolios and market presence, industry participants are investing in research and development to produce innovative glycomics enzymes with expanded functionality. For instance, Creative Proteomics offers services such as O-Glycan linkage analysis service, N-glycan linkage analysis service, glycoproteomics service, O-glycan profiling, and N-glycan profiling, among others.

The market is projected to grow in the North American region.

New drug development is becoming necessary as the burden of chronic diseases rises. Glycans have been connected to a wide range of illnesses, such as cancer, heart problems, and infectious diseases, and are involved in several biological processes. For instance, the estimated number of new cases of cancer in the United States was 9,83,160 among males and 9,34,870 among females as per the American Cancer Society.

Moreover, determining possible therapeutic targets and creating efficient medication designs require an understanding of the glycan profiles and how they interact with proteins and cells. Improved drug screening platforms, companion diagnostics, and glycan-based therapies have also been developed as a result of integration with drug discovery and development processes in the United States.

Further, the demand for research and technologies in the United States has been driven by the focus on targeting glycans in drug discovery and development, making this a major growth prospect. For instance, hyaluronan, a naturally occurring glycosaminoglycan disaccharide unit, has numerous uses in medicine. It is applied to surgical wounds and plays a crucial role in the management of osteoarthritis . Regional industry growth is being aided by the rising demand for advanced therapeutics and the government's increased financing of research and development. For instance, the NIH launched the Glycoscience program to encourage glycobiology research in glycan science, in April 2023 . The Glycoscience program has created several tools, resources, and information to help researchers unfamiliar with glycans incorporate them into their studies. This covers methods for recognizing particularly challenging glycans, probes to investigate glycans in bacterial cell walls, standards for glycan chemical synthesis, approaches for high-throughput glycan investigations, and instructional materials related to glycoscience.

Many products have facilitated the execution of glycomics experiments and investigations by academic, pharmaceutical, and research institute researchers. Some businesses also concentrate on converting research into useful commercial applications. They create and sell glycan-based goods for a range of markets, including nutraceuticals, biopharmaceuticals, and diagnostics. For instance, Agilent Technologies Inc. introduced the Agilent BioTek 406 FX washer dispenser in June 2023. It is a small device that combines plate-washing and multipurpose reagent dispensing capabilities. With its extended liquid handling features, the BioTek 406 FX is intended for both standalone benchtop use and integration into automated systems.

Additionally, Thermo Fisher Scientific Inc. introduced the DynaSpinTM Single-Use Centrifuge system in September 2022. The system is specifically made to offer the best single-use option for harvesting cell cultures on a large scale. Moreover, by lowering the quantity of depth filtration cartridges needed to finish the harvest process, it enhances and simplifies harvesting for cell culture separation in single-use bioprocesses.

Key Players:

  • Merck KGaA is a leading player in the glycomics market, offering a range of products and solutions for glycan analysis and research. With a strong emphasis on innovation and technology, Merck KGaA provides researchers with tools and reagents to advance glycomics research.
  • Thermo Fisher Scientific Inc. is another prominent player in the glycomics market, known for its comprehensive portfolio of analytical instruments, consumables, and software solutions tailored for glycan analysis. Its cutting-edge technologies enable precise characterization and quantification of complex glycomes.
  • Takara Bio Inc. specializes in providing high-quality reagents, kits, and instruments for glycomics research. Focusing on simplifying workflows and enhancing experimental reproducibility, it offers innovative solutions to support glycan analysis and accelerate discoveries in the field.

Segmentation:

By Product

  • Enzymes
  • Instruments
  • Kits
  • Others

By Application

  • Drug Discovery
  • Diagnostics
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the Stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLYCOMICS MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Enzymes
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Instruments
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Kits
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Trends and Opportunities
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLYCOMICS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Drug Discovery
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Diagnostics
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Others
    • 6.4.1. Market Trends and Opportunities
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLYCOMICS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
      • 7.2.3.1. United States
        • 7.2.3.1.1. Market Trends and Opportunities
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Trends and Opportunities
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Trends and Opportunities
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Product
    • 7.3.2. By Application
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Trends and Opportunities
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Trends and Opportunities
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Trends and Opportunities
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Product
    • 7.4.2. By Application
    • 7.4.3. By Country
      • 7.4.3.1. Germany
        • 7.4.3.1.1. Market Trends and Opportunities
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. France
        • 7.4.3.2.1. Market Trends and Opportunities
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. UK
        • 7.4.3.3.1. Market Trends and Opportunities
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Others
        • 7.4.3.4.1. Market Trends and Opportunities
        • 7.4.3.4.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Product
    • 7.5.2. By Application
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Trends and Opportunities
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Trends and Opportunities
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Trends and Opportunities
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Product
    • 7.6.2. By Application
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Trends and Opportunities
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. India
        • 7.6.3.2.1. Market Trends and Opportunities
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. Japan
        • 7.6.3.3.1. Market Trends and Opportunities
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Trends and Opportunities
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Taiwan
        • 7.6.3.5.1. Market Trends and Opportunities
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Thailand
        • 7.6.3.6.1. Market Trends and Opportunities
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Trends and Opportunities
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Trends and Opportunities
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Merck KGaA
  • 9.2. Thermo Fisher Scientific Inc.
  • 9.3. Takara Bio Inc.
  • 9.4. Shimadzu Corporation
  • 9.5. Agilent Technologies, Inc.
  • 9.6. New England Biolabs
  • 9.7. Asparia Glycomics
  • 9.8. Z Biotech, LLC.
  • 9.9. QA-Bio